论文部分内容阅读
目的:探讨Survivin在人非小细胞肺癌组织中表达、临床意义及其与VEGF表达的相关性。方法:采用免疫组织化学(Envision二步法)检测Survivin和VEGF在116例肺鳞癌、腺癌组织及15例肺良性病变组织中的表达情况。结果:Survivin、VEGF的阳性率分别为62.1%(72/116)、72.4%(84/116),显著高于肺良性病变组织的0(0/15)、13.3%(2/15);Survivin表达与非小细胞肺癌的低分化(P<0.05)、淋巴结转移呈正相关(P<0.05),与患者预后负相关(P<0.05);VEGF的表达与肺癌组织的分化程度、TNM分期及淋巴结转移均有关(P<0.05);并且Survivin表达与VEGF表达呈正相关(P<0.05)。结论:Survivin有望成为肺癌诊断和基因治疗的新靶点。
Objective: To investigate the expression of Survivin in human non-small cell lung cancer and its clinical significance and its correlation with VEGF expression. Methods: The expressions of Survivin and VEGF in 116 squamous cell carcinoma of the lung, adenocarcinoma and 15 cases of benign lung lesions were detected by immunohistochemistry (Envision two-step method). Results: The positive rates of Survivin and VEGF were 62.1% (72/116) and 72.4% (84/116) respectively, which were significantly higher than those in benign lung tissues (0/15, 13.3%, 2/15) (P <0.05), lymph node metastasis (P <0.05), and negatively correlated with the prognosis of patients (P <0.05). The expression of VEGF correlated with the differentiation of lung cancer, TNM stage and lymph node (P <0.05). Survivin expression was positively correlated with VEGF expression (P <0.05). Conclusion: Survivin is expected to become a new target for lung cancer diagnosis and gene therapy.